Match!

Predictors of Anastomotic Failure After Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy: Does Technique Matter?

Published on Mar 1, 2020in Annals of Surgical Oncology3.681
· DOI :10.1245/s10434-019-07964-x
Jason T. Wiseman8
Estimated H-index: 8
(OSU: Ohio State University),
Jason T. Wiseman1
Estimated H-index: 1
(OSU: Ohio State University)
+ 24 AuthorsJordan M. Cloyd9
Estimated H-index: 9
(OSU: Ohio State University)
Abstract
Background Anastomotic failure (AF) after cytoreductive surgery (CRS) with hyperthermic intraperitoneal chemotherapy (HIPEC) remains a dreaded complication. Whether specific factors, including anastomotic technique, are associated with AF is poorly understood.
  • References (38)
  • Citations (1)
📖 Papers frequently viewed together
2 Citations
5 Citations
78% of Scinapse members use related papers. After signing in, all features are FREE.
References38
Newest
Background Anastomotic leakage after colorectal surgery is a complication that requires additional treatments strongly affecting the economic outcomes. We evaluated the use of resources and the economic burden associated with anastomotic leaks following colorectal surgery.
1 CitationsSource
#1Jason M. Foster (UNMC: University of Nebraska Medical Center)H-Index: 10
#2Richard Sleightholm (UNMC: University of Nebraska Medical Center)H-Index: 7
Last. Lynette M Smith (UNMC: University of Nebraska Medical Center)H-Index: 48
view all 8 authors...
Importance Currently, rates of referral of patients with peritoneal metastasis in the United States who qualify for cytoreductive surgery combined with hyperthermic intraperitoneal chemotherapy (CRS/HIPEC) are low, in part because of the misperception of high morbidity and mortality rates. However, patients requiring major gastrointestinal surgical procedures with similar complication rates are routinely referred. Objective To evaluate the relative safety of CRS/HIPEC. Design, Setting, and Parti...
7 CitationsSource
#1Bruce Chamberlain (Genesis HealthCare)H-Index: 3
#2Michelle Rhiner (LLUMC: Loma Linda University Medical Center)H-Index: 1
Last. Robert J. IsraelH-Index: 13
view all 5 authors...
1Background: A post-hoc analysis of pooled data from two randomized, double-blind studies and their open-label extensions evaluated whether baseline characteristics and efficacy endpoints differ be...
2 CitationsSource
#1François QuenetH-Index: 25
#2Dominique EliasH-Index: 82
Last. Olivier GlehenH-Index: 46
view all 17 authors...
LBA3503Background: Promising results have been obtained during the last decade using cytoreductive surgery (CRS) plus HIPEC for selected patients with colorectal PC who are amenable to complete macroscopic resection. This is the first trial to evaluate the specific role of HIPEC, after CRS, for the treatment of PC of colorectal origin. Methods: Prodige 7 is a randomized phase III, multicenter trial. Patients with histologically proven and isolated PC, peritoneal cancer index (PCI) ≤25 were eligi...
66 CitationsSource
16 CitationsSource
#1Willemien J. van Driel (NKI-AVL: Netherlands Cancer Institute)H-Index: 9
#2Simone N. Koole (NKI-AVL: Netherlands Cancer Institute)H-Index: 1
Last. Gabe S. Sonke (NKI-AVL: Netherlands Cancer Institute)H-Index: 28
view all 17 authors...
The majority of patients with ovarian cancer (OC) receive an initial diagnosis of advanced disease that has spread from the ovaries to the peritoneal surface. The most effective treatment for patients with advanced disease is cytoreductive surgery followed by systemic chemotherapy. As an alternative, interval cytoreductive surgery is performed after 3 cycles of chemotherapy. Following these treatments, the primary site of disease recurrence is the peritoneal surface. Delivery of chemotherapy by ...
1 CitationsSource
#1Rebecca M. Dodson (Wake Forest Baptist Medical Center)H-Index: 15
#2Michael Kuncewitch (Wake Forest Baptist Medical Center)H-Index: 2
Last. Edward A. Levine (Wake Forest Baptist Medical Center)H-Index: 54
view all 5 authors...
4 CitationsSource
#1Willemien J. van Driel (NKI-AVL: Netherlands Cancer Institute)H-Index: 9
#2Simone N. Koole (NKI-AVL: Netherlands Cancer Institute)H-Index: 1
Last. Gabe S. Sonke (NKI-AVL: Netherlands Cancer Institute)H-Index: 28
view all 17 authors...
Abstract Background Treatment of newly diagnosed advanced-stage ovarian cancer typically involves cytoreductive surgery and systemic chemotherapy. We conducted a trial to investigate whether the addition of hyperthermic intraperitoneal chemotherapy (HIPEC) to interval cytoreductive surgery would improve outcomes among patients who were receiving neoadjuvant chemotherapy for stage III epithelial ovarian cancer. Methods In a multicenter, open-label, phase 3 trial, we randomly assigned 245 patients...
174 CitationsSource
#1Saori Goto (Kyoto University)H-Index: 5
#2Suguru Hasegawa (Fukuoka University)H-Index: 26
Last. Yoshiharu Sakai (Kyoto University)H-Index: 39
view all 8 authors...
Background In rectal cancer, anastomotic leakage was reported to have a negative impact on both short- and long-term outcomes. However, there is limited data on the impact of anastomotic leakage on oncologic outcomes in patients with colon cancer. We aimed to evaluate the impact of anastomotic leakage on disease recurrence and long-term survival after curative resection of colon cancer. Methods This multicenter, retrospective cohort study of 4,919 consecutive patients utilized data from the Japa...
12 CitationsSource
#1Konstantinos Chouliaras (Wake Forest Baptist Medical Center)H-Index: 5
#2Edward A. Levine (Wake Forest Baptist Medical Center)H-Index: 54
Last. Konstantinos I. Votanopoulos (Wake Forest Baptist Medical Center)H-Index: 21
view all 5 authors...
Background Gastrointestinal leak (GIL) after cytoreductive surgery with heated intraperitoneal chemotherapy (CRS/HIPEC) is associated with significant morbidity and mortality. This study aimed to identify GIL prognostic factors and its impact on overall survival.
9 CitationsSource
Cited By1
Newest
#1JC Chen (The Ohio State University Wexner Medical Center)
#2Eliza W. Beal (The Ohio State University Wexner Medical Center)H-Index: 10
Last. Jordan M. Cloyd (The Ohio State University Wexner Medical Center)H-Index: 9
view all 6 authors...
BACKGROUND: Cytoreductive surgery (CRS) with or without hyperthermic intraperitoneal chemotherapy (HIPEC) is indicated for patients with peritoneal dissemination of appendiceal cancer. The role of neoadjuvant chemotherapy (NAC) before CRS-HIPEC remains controversial. METHODS: A retrospective review of adult patients who underwent CRS +/- HIPEC for metastatic appendiceal cancer between 2000-2017 was performed. Patients who received NAC followed by surgery were compared with those who underwent su...
Source
#1Jason T. Wiseman (OSU: Ohio State University)H-Index: 8
#2Jordan M. Cloyd (OSU: Ohio State University)H-Index: 9
Source